Study to Investigate the Safety and Efficacy of Tregalizumab in Subjects (MTX-IR) With Active Rheumatoid Arthritis

PHASE2TerminatedINTERVENTIONAL
Enrollment

321

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Tregalizumab

humanized anti-CD4 mAb

DRUG

Placebo

identical end formulation buffer

Trial Locations (84)

29406

Study Site 04, North Charleston

38305

Study Site 05, Jackson

62704

Study Site 01, Springfield

68516

Study Site 03, Lincoln

77004

Study Site 09, Houston

77450

Study Site 10, Katy

85253

Study Site 07, Paradise Valley

07012

Study Site 02, Clifton

Unknown

Study Site 01, Plovdiv

Study Site 06, Plovdiv

Study Site 02, Sofia

Study Site 04, Sofia

Study Site 07, Sofia

Study Site 05, Stara Zagora

Study Site 03, Varna

Study Site 02, Rimouski

Study Site 01, Saint-Jérôme

Study Site 03, Bruntál

Study Site 05, Ostrava

Study Site 01, Prague

Study Site 04, Prague

Study Site 08, Prague

Study Site 09, Prague

Study Site 02, Uherské Hradiště

Study Site 07, Uherské Hradiště

Study Site 06, Zlín

Study Site 01, Tallinn

Study Site 03, Berlin

Study Site 04, Frankfurt

Study Site 06, München

Study Site 02, Ratingen

Study Site 01, Zerbst

Study Site 03, Balatonfüred

Study Site 02, Budapest

Study Site 04, Budapest

Study Site 05, Budapest

Study Site 06, Gyula

Study Site 01, Veszprém

Study Site 01, Kaunas

Study Site 02, Vilnius

Study Site 06, León

Study Site 05, Mexico City

Study Site 08, Mexico City

Study Site 02, Chihuahua City

Study Site 03, Distrito Federal

Study Site 08, Bialystok

Study Site 05, Bydgoszcz

Study Site 10, Elblag

Study Site 04, Gdynia

Study Site 02, Katowice

Study Site 03, Krakow

Study Site 06, Krakow

Study Site 09, Poznan

Study Site 01, Warsaw

Study Site 07, Warsaw

Study Site 08, Kemerovo

Study Site 11, Kemerovo

Study Site 04, Kursk

Study Site 03, Moscow

Study Site 07, Moscow

Study Site 10, Moscow

Study Site 05, Omsk

Study Site 09, Saratov

Study Site 06, Smolensk

Study Site 01, Tomsk

Study Site 02, Yaroslavl

Study Site 01, Belgrade

Study Site 02, Belgrade

Study Site 04, Belgrade

Study Site 03, Niška Banja

Study Site 03, Bratislava

Study Site 04, Kosice - Saca

Study Site 05, Lučenec

Study Site 02, Považská Bystrica

Study Site 01, Rimavská Sobota

Study Site 08, Donetsk

Study Site 01, Kharkiv

Study Site 02, Kharkiv

Study Site 03, Kyiv

Study Site 04, Kyiv

Study Site 05, Vinnytsia

Study Site 06, Vinnytsia

Study Site 07, Vinnytsia

Study Site 09, Zaporizhzhia

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

AbbVie

INDUSTRY

lead

Biotest

INDUSTRY